Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Indicator #3 The cost of Financialization: More Spent on Shareholders than R&D (FIGURE 3) Ratio of Spending on R&D vs Shareholder Enrichment for Leading Pharmaceutical Companies 2020-2024 The figure shows the ratio of total spending on R&D versus shareholder enrichment (stock buybacks plus shareholder dividends) for 15 peer companies during the five year period from 2020-2024
Remove along the same angle you inserted
ANDA filing activity, Paragraph IV certifications, Orange Book changes, and biosimilar application submissions are all publicly available signals that provide advance warning of competitive entry intentions
Cuban suggested that his pricing, with the markup and the labor and shipping fees, might have skewed the costs and that bundling multiple drugs together under one shipping fee could be cheaper
US$ 26.67
US$ 24.62
US$ 20.49
US$ 24.36
US$ 27.61
